pioglitazone has been researched along with ramipril in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (33.33) | 29.6817 |
| 2010's | 4 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Cersosimo, E; Cusi, K; DeFronzo, R; Fernandez, M; Musi, N; Sriwijilkamol, AA; Triplitt, C; Wajcberg, E | 1 |
| Berry, C; Bourassa, MG | 1 |
| Dekordi, LA; Forst, T; Fuchs, W; Hanefeld, M; Kleine, I; Müller, J; Pfützner, A | 1 |
| Cernecka, H; Goris, M; Henning, RH; Klimas, J; Krenek, P; Kyselovic, J; Mesarosova, L; Ochodnicky, P; van Dokkum, RP | 1 |
1 review(s) available for pioglitazone and ramipril
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
2 trial(s) available for pioglitazone and ramipril
| Article | Year |
|---|---|
Addition of pioglitazone and ramipril to intensive insulin therapy in type 2 diabetic patients improves vascular dysfunction by different mechanisms.
Topics: Antihypertensive Agents; Blood Flow Velocity; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Drug Therapy, Combination; Forearm; Glucose Clamp Technique; Glycated Hemoglobin; Hispanic or Latino; Humans; Hypoglycemic Agents; Inflammation; Insulin; Insulin Infusion Systems; Pioglitazone; Placebos; Ramipril; Thiazolidinediones | 2008 |
Effect of pioglitazone and ramipril on biomarkers of low-grade inflammation and vascular function in nondiabetic patients with increased cardiovascular risk and an activated inflammation: results from the PIOace study.
Topics: Adult; Aged; Antihypertensive Agents; Biomarkers; Blood Vessels; Cardiovascular Diseases; Diabetes Complications; Double-Blind Method; Female; Humans; Hypoglycemic Agents; Inflammation; Male; Middle Aged; Pioglitazone; Placebos; Ramipril; Risk Factors; Severity of Illness Index; Thiazolidinediones; Up-Regulation | 2011 |
3 other study(ies) available for pioglitazone and ramipril
| Article | Year |
|---|---|
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Prevention and noninvasive management of coronary atherosclerosis in patients with diabetes.
Topics: Antihypertensive Agents; Cholesterol, HDL; Cholesterol, LDL; Coronary Artery Disease; Diabetes Mellitus; Diabetic Angiopathies; Humans; Hyperglycemia; Hypoglycemic Agents; Hypolipidemic Agents; Insulin Resistance; Life Style; Myocardial Infarction; Obesity; Pioglitazone; Piperidines; Platelet Aggregation Inhibitors; Prediabetic State; Pyrazoles; Ramipril; Rimonabant; Risk Assessment; Thiazolidinediones; Triglycerides; Weight Loss | 2008 |
Pioglitazone, a PPARγ agonist, provides comparable protection to angiotensin converting enzyme inhibitor ramipril against adriamycin nephropathy in rat.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Aorta; Blood Pressure; Disease Progression; Doxorubicin; Endothelium, Vascular; Gene Expression Regulation; Kidney Diseases; Kidney Glomerulus; Kidney Tubules; Male; Pioglitazone; PPAR gamma; Proteinuria; Ramipril; Rats; Rats, Wistar; Renin-Angiotensin System; Thiazolidinediones | 2014 |